Search: onr:"swepub:oai:DiVA.org:uu-469229" > Risk classification...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 10434naa a2200997 4500 | |
001 | oai:DiVA.org:uu-469229 | |
003 | SwePub | |
008 | 220308s2022 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:148882571 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4692292 URI |
024 | 7 | a https://doi.org/10.1182/bloodadvances.20210048812 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1488825712 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Menghrajani, Kamalu Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.4 aut |
245 | 1 0 | a Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML |
264 | c 2022-02-01 | |
264 | 1 | b American Society of Hematology,c 2022 |
338 | a print2 rdacarrier | |
520 | a Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1.27; P = .01; HR, 1.71; P < .001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1.26; P = .002, and HR, 1.47; P < .001), as was overall survival (HR, 1.32; P < .001, and HR, 1.45; P < .001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
700 | 1 | a Gomez-Arteaga, Alexandrau Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.4 aut |
700 | 1 | a Madero-Marroquin, Rafaelu Icahn Sch Med, Dept Med, Mt Sinai St Luke, New York, NY USA.4 aut |
700 | 1 | a Zhang, Mei-Jieu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA.4 aut |
700 | 1 | a Bo-Subait, Khalidu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.4 aut |
700 | 1 | a Sanchez, Jonathanu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.4 aut |
700 | 1 | a Wang, Hai-Linu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.4 aut |
700 | 1 | a Aljurf, Mahmoudu King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.4 aut |
700 | 1 | a Assal, Ameru Columbia Univ Irving Med Ctr, Dept Med, Bone Marrow Transplant & Cell Therapy Program, New York, NY USA.4 aut |
700 | 1 | a Bacher, Vera Ulrikeu Univ Bern, Bern Univ Hosp, Dept Hematol, Inselspital, Bern, Switzerland.4 aut |
700 | 1 | a Badawy, Sherif M.u Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol & Stem Cell Transplant, Chicago, IL 60611 USA.;Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA.4 aut |
700 | 1 | a Bejanyan, Nelliu H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.4 aut |
700 | 1 | a Bhatt, Vijaya Raju Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.4 aut |
700 | 1 | a Bredeson, Christopheru Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada.;Ottawa Hosp Res Inst, Ottawa, ON, Canada.4 aut |
700 | 1 | a Byrne, Michaelu Vanderbilt Univ, Div Hematol & Oncol, Med Ctr, Nashville, TN USA.4 aut |
700 | 1 | a Castillo, Paulu UF Hlth Shands Childrens Hosp, Dept Pediat Coll Med, Div Hematol & Oncol, Gainesville, FL USA.4 aut |
700 | 1 | a Cerny, Janu Univ Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA.4 aut |
700 | 1 | a Chhabra, Saurabhu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.4 aut |
700 | 1 | a Ciurea, Stefan Octavianu Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA.4 aut |
700 | 1 | a DeFilipp, Zachariahu Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA.4 aut |
700 | 1 | a Farhadfar, Noshau Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA.4 aut |
700 | 1 | a Gadalla, Shahinazu NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA.4 aut |
700 | 1 | a Gale, Robert Peteru Imperial Coll London, Haematol Res Ctr, Dept Immunol & Inflammat, London, England.4 aut |
700 | 1 | a Ganguly, Siddharthau Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.4 aut |
700 | 1 | a Gowda, Lohithu Yale Univ, Sch Med, Dept Med,Sect Hematol, Yale Comprehens Canc Ctr,Yale New Haven Hosp, New Haven, CT 06510 USA.4 aut |
700 | 1 | a Grunwald, Michael R.u Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA.4 aut |
700 | 1 | a Hashmi, Shahrukhu Mayo Clin, Dept Internal Med, Rochester, MN USA.;King Faisal Specialist Hosp & Res Ctr, Oncol Ctr, Riyadh, Saudi Arabia.4 aut |
700 | 1 | a Hildebrandt, Gerhardu Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.4 aut |
700 | 1 | a Kanakry, Christopher G.u NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.4 aut |
700 | 1 | a Kansagra, Ankitu UT Southwestern Med Ctr, Blood & Marrow Transplant Program, Dallas, TX USA.4 aut |
700 | 1 | a Khimani, Farhadu H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.4 aut |
700 | 1 | a Krem, Maxwellu Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY USA.4 aut |
700 | 1 | a Lazarus, Hillardu Case Western Reserve Univ, Univ Hosp Case Med Ctr, Dept Med, Cleveland, OH 44106 USA.;Case Western Reserve Univ, Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.4 aut |
700 | 1 | a Liu, Hongtaou Univ Chicago Med, Sect Hematol Oncol, Chicago, IL USA.4 aut |
700 | 1 | a Martino, Rodrigou Hosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain.4 aut |
700 | 1 | a Michelis, Fotios, Vu Princess Margaret Canc Ctr, Allogene Blood & Marrow Transplant Program, Toronto, ON, Canada.4 aut |
700 | 1 | a Nathan, Sunitau Rush Univ, Med Ctr, Sect Bone Marrow Transplant & Cell Therapy, Chicago, IL 60612 USA.4 aut |
700 | 1 | a Nishihori, Taigau Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.4 aut |
700 | 1 | a Olsson, Richardu Uppsala universitet,Institutionen för medicinsk cellbiologi,Centrum för klinisk forskning i Sörmland (CKFD),Hematologi,Karolinska Inst, Dept Lab Med, Stockholm, Sweden.4 aut0 (Swepub:uu)riols677 |
700 | 1 | a Reshef, Ranu Columbia Univ, Med Ctr, Blood & Marrow Transplantat Program, New York, NY USA.;Columbia Univ, Columbia Ctr Translat Immunol, Med Ctr, New York, NY USA.4 aut |
700 | 1 | a Rizzieri, Davidu Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.4 aut |
700 | 1 | a Rowe, Jacob M.u Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel.4 aut |
700 | 1 | a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.4 aut |
700 | 1 | a Seo, Sachikou Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.4 aut |
700 | 1 | a Sharma, Akshayu St Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, 332 N Lauderdale St, Memphis, TN 38105 USA.4 aut |
700 | 1 | a Solh, Melhemu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.4 aut |
700 | 1 | a Ustun, Celalettinu Rush Univ, Med Ctr, Hematol Oncol & Cell Therapy, Chicago, IL 60612 USA.4 aut |
700 | 1 | a Verdonck, Leo F.u Isala Clin, Dept Hematol & Oncol, Zwolle, Netherlands.4 aut |
700 | 1 | a Hourigan, Christopheru NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.4 aut |
700 | 1 | a Sandmaier, Brendau Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.;Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.4 aut |
700 | 1 | a Litzow, Marku Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA.4 aut |
700 | 1 | a Kebriaei, Partowu Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA.4 aut |
700 | 1 | a Weisdorf, Danielu Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA.4 aut |
700 | 1 | a Zhang, Yanmingu Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.4 aut |
700 | 1 | a Tallman, Martin S.u Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.;Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.4 aut |
700 | 1 | a Saber, Waelu Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.4 aut |
710 | 2 | a Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.b Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.4 org |
773 | 0 | t Blood Advancesd : American Society of Hematologyg 6:3, s. 828-847q 6:3<828-847x 2473-9529x 2473-9537 |
856 | 4 | u https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2021004881/1823739/bloodadvances.2021004881.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-469229 |
856 | 4 8 | u https://doi.org/10.1182/bloodadvances.2021004881 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:148882571 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.